McGrath Yvonne 4
4 · iTeos Therapeutics, Inc. · Filed Mar 14, 2022
Insider Transaction Report
Form 4
McGrath Yvonne
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-03-11+85,000→ 85,000 totalExercise: $36.21Exp: 2032-03-11→ Common Stock (85,000 underlying)
Footnotes (1)
- [F1]This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.